AALL1331: Risk Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Protocol: 
AAAP9840
Phase: 
III

AALL1331: Risk Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Are you Eligible? (Inclusion Criteria)

-Subjects must be at least 1 year and up to 30 years of age at the time of
study entry.
-Patients must have first relapse of B-ALL. Allowable sites of disease
include isolated bone marrow, combined bone marrow and CNS and/or testicular
disease, and isolated CNS and/or testicular disease (these are the only two
extramedullary sites allowed)
-Patients must have not had prior treatment with blinatumomab
-Patients must also meet all other eligibility criteria as outlined in the
study protocol.

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States